Neuronetics Valuation Multiples

Neuronetics Overview

About Neuronetics

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

Founded

2003

HQ

Employees

716

Website

neurostar.com

Sectors

Medical Devices

Financials (LTM)

Revenue: $153M

EBITDA: ($19M)

EV

$156M

Valuation Multiples

Multiples.vc

Start free trial

Neuronetics Financials

Neuronetics reported last 12-month revenue of $153M and negative EBITDA of ($19M).

In the same LTM period, Neuronetics generated $74M in gross profit, ($19M) in EBITDA losses, and had net loss of ($38M).

Neuronetics P&L

In the most recent fiscal year, Neuronetics reported revenue of $149M and EBITDA of ($22M).

Neuronetics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Neuronetics Stock Performance

Neuronetics has current market cap of $94M, and enterprise value of $156M.

Neuronetics' stock price is $1.35.

Neuronetics Valuation Multiples

Neuronetics trades at 1.0x EV/Revenue multiple, and (8.2x) EV/EBITDA.

Neuronetics Financial Valuation Multiples

As of April 11, 2026, Neuronetics has market cap of $94M and EV of $156M.

Equity research analysts estimate Neuronetics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Neuronetics has a P/E ratio of (2.5x).

Neuronetics Margins & Growth Rates

Neuronetics' revenue in the last 12 month grew by 10%.

Neuronetics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Neuronetics' rule of 40 is 1% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Neuronetics' rule of X is 15% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Neuronetics Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Neuronetics M&A Activity

Neuronetics acquired XXX companies to date.

Last acquisition by Neuronetics was on XXXXXXXX, XXXXX. Neuronetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Neuronetics Investment Activity

Neuronetics invested in XXX companies to date.

Neuronetics made its latest investment on XXXXXXXX, XXXXX. Neuronetics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).